Landscape of <i>FGF</i>/<i>FGFR</i> Alterations in 12,372 Chinese Cancer Patients

Zuo, Wei; He, Yan; Li, Wei; Wu, Hao; Zhao, Zhengyi; Zhang, Yuzi; Chen, Shiqing; Yin, Yongmei

doi:10.7150/jca.49269



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2020; 11(22):6695-6699. doi:10.7150/jca.49269 This issue Cite

Research Paper

Landscape of FGF/FGFR Alterations in 12,372 Chinese Cancer Patients

Wei Zuo^1*, Yan He^2*, Wei Li³, Hao Wu³, Zhengyi Zhao⁴, Yuzi Zhang⁴, Shiqing Chen⁴, Yongmei Yin^3✉

1. Department of Respiratory, The First Affiliated Hospital of Nanchang University, Jiangxi, China
2. The Second Shenzhen People's hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
3. Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
4. The Medical Department, 3D Medicines, Inc. Shanghai, China
*Dr. Wei Zuo and Yan He contributed equally to this work and serve as co-first authors.

Citation:

Zuo W, He Y, Li W, Wu H, Zhao Z, Zhang Y, Chen S, Yin Y. Landscape of FGF/FGFR Alterations in 12,372 Chinese Cancer Patients. J Cancer 2020; 11(22):6695-6699. doi:10.7150/jca.49269. https://www.jcancer.org/v11p6695.htm

Other styles

Abstract

Purpose: The aberrant of fibroblast growth factors and their receptors (FGF/FGFR) is an emerging target in the treatment of solid tumors. This study aimed to explore the landscape of FGF/FGFR alterations in a large cohort of cancer patients.

Material and Methods: The formalin-fixed paraffin-embedded specimens of cancer patients who have underwent next-generation sequencing (NGS) from 2017 to 2019 in 3DMed Clinical Laboratory Inc. were included in this study.

Findings: Of 12,372 Chinese cancer patients with more than 20 tumor types (60% male, median age, 58.0 [IQR, 49.0-66.0]), genomic alterations in FGF, FGFR, and both were observed in 895 (7.2%), 862 (7.0%), and 186 (1.5%) patients, respectively. The highest prevalence of FGF/FGFR mutations fell in esophagus cancer (61.6%, 98/159) and urinary tract cancer (52.7%, 145/275). The most common pathway-level mutations were FGFR single nucleotide variants (635, 5.1%) and FGF amplifications (628, 5.1%). The microsatellite instability status was negatively associated with amplifications (p=0.0017).

Conclusion: FGF/FGFR alterations were widely occurred in cancer patients, and the mutational landscape may contribute to the further study design and development of FGF/FGFR inhibitors.

Keywords: Fibroblast growth factor receptor, Next-generation sequencing, Solid tumor

Citation styles

APA

Zuo, W., He, Y., Li, W., Wu, H., Zhao, Z., Zhang, Y., Chen, S., Yin, Y. (2020). Landscape of FGF/FGFR Alterations in 12,372 Chinese Cancer Patients. Journal of Cancer, 11(22), 6695-6699. https://doi.org/10.7150/jca.49269.

ACS

Zuo, W.; He, Y.; Li, W.; Wu, H.; Zhao, Z.; Zhang, Y.; Chen, S.; Yin, Y. Landscape of FGF/FGFR Alterations in 12,372 Chinese Cancer Patients. J. Cancer 2020, 11 (22), 6695-6699. DOI: 10.7150/jca.49269.

NLM

CSE

Zuo W, He Y, Li W, Wu H, Zhao Z, Zhang Y, Chen S, Yin Y. 2020. Landscape of FGF/FGFR Alterations in 12,372 Chinese Cancer Patients. J Cancer. 11(22):6695-6699.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.